WallStSmart
NKTR

Nektar Therapeutics

NASDAQ: NKTR · HEALTHCARE · BIOTECHNOLOGY

$85.04
+2.21% today

Updated 2026-04-30

Market cap
$2.76B
P/E ratio
P/S ratio
50.03x
EPS (TTM)
$-9.73
Dividend yield
52W range
$8 – $109
Volume
1.1M

Nektar Therapeutics (NKTR) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Operating cash flow$-92.72M$146.30M$-145.78M$39.74M$-55.87M$-113.74M$-129.76M$-38.53M$-142.01M$-73.08M$-117.02M$-80.41M$718.21M$-328.68M$-313.29M$-412.66M$-304.01M$-192.61M$-175.71M$-208.51M
Capital expenditures$22.52M$32.80M$18.86M$20.70M$31.46M$9.72M$10.58M$4.09M$9.98M$11.20M$6.39M$9.68M$14.24M$26.29M$7.26M$14.99M$5.68M$865000.00$1.47M$171000.00
Depreciation
Stock-based comp$9700.00$14.78M$9.87M$10.33M$17.40M$18.89M$16.20M$17.71M$17.02M$19.67M$25.85M$36.62M$88.10M$99.80M$94.26M$94.67M$57.32M$33.39M$21.61M$12.65M
Free cash flow$-115.24M$113.51M$-164.64M$19.04M$-87.33M$-123.46M$-140.34M$-42.62M$-151.98M$-84.28M$-123.42M$-90.09M$703.98M$-354.97M$-320.55M$-427.65M$-309.68M$-193.47M$-177.18M$-208.68M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Share repurchases
Debt repayment
Net change in cash$-2.44M$10.13M$13.63M$-26.70M$43.20M$4.07M$-54.88M$190.24M$-98.44M$102.57M$-173.65M